drugset / Trial / NCT00379249

Rosuvastatin ORBITAL Germany

NCT00379249

Phase 3 Completed 8000 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related costs during the 36 month.

Timeline

Start
2002-02
Primary completion
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Background Rosuvastatin Small molecule

Indications